Pharmaceutical composition which reduces or eliminates drug abuse potential

Abstract

A pharmaceutical composition which reduces or eliminates the drug abuse potential of central nervous system stimulant comprising: (a) a drug selected from the group consisting of methylphenidate, amphetamine, methamphetamine, and combinations thereof; and (b) a gel forming polymer wherein the gel forming polymer is a polymer that forms a gel when contacted with moisture or placed in an aqueous solution. The present invention is based on the discovery that a central nervous system stimulant such as methylphenidate in combination with a gel forming polymer reduces or eliminates drug abuse potential by swelling in the presence of moisture, and thus, preventing nasal absorption and injectability of the drug.

1 - 23 . (canceled)  
   
   
       24 . A pharmaceutical composition which reduces or eliminates the drug abuse potential of central nervous system stimulant comprising: 
 a) a drug selected from the group consisting of methylphenidate, amphetamine, methamphetamine, and combinations thereof; and    b) a gel forming polymer wherein the gel forming polymer is a polymer that forms a gel when contacted with moisture or placed in an aqueous solution.    
   
   
       25 . The composition according to  claim 24  wherein the gel forming polymer is selected from the group consisting of a polysaccharide, gelatin, polyglucosamine, hydrophilic colloid, cross-linkable hydrophilic polymer, an acrylate ester polymerized with a monomer selected from the group consisting of a vinyl-substituted heterocyclic compound containing at least one of a nitrogen or a sulfur atom, (meth)acrylamide, a mono- or di-C 1 -C 4  alkylamino C 1 -C 4  alkyl (meth)acrylate, and a mono or di-C 1 -C 4  alkylamino C 1 -C 4  alkyl acrylamide and combinations thereof.  
   
   
       26 . The composition according to  claim 25  wherein the polysaccharide is selected from the group consisting of an agar, carrageenan, modified cellulose and starch.  
   
   
       27 . The composition according to  claim 26  wherein the polysaccharide is selected from the group consisting of hydroxyethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethyl cellulose, hydroxypropyl methyl cellulose phthalate or acetate succinate, cellulose acetate phthalate, methyl cellulose phthalate, microcrystalline cellulose, a cold water swelling starch, sodium carboxymethyl starch and starch acetate phthalate.  
   
   
       28 . The composition according to  claim 25  wherein the hydrophilic colloid is a derivative of alginic acid.  
   
   
       29 . The composition according to  claim 28  wherein the derivative of alginic acid is selected from the group consisting of calcium alginate, sodium alginate, potassium alginate and propylene glycol alginate.  
   
   
       30 . The composition according to  claim 25  wherein the cross-linkable hydrophilic polymer is selected from the group consisting of polyvinyl pyrrolidone, carboxymethylamide, potassium methacrylatedivinylbenzene, polyvinylalcohol, polyoxyethyleneglycol, polyethylene glycol, carboxypolymethylene, polyacrylic acid, polymethacrylic acid, polyvinyl pyrrolidone/acrylic acid, polymethyl vinyl ether/maleic anhydride, polyethylene/maleic anhydride, polymethyl methacrylate, polyethyl methacrylate, polybutyl methacylate, polyisobutyl methacrylate, polyhexyl methacrylate, polyisodecyl methacrylate, polylauryl methacrylate, polyphenyl methacrylate, polymethyl acrylate, polyisopropyl acrylate, polyisobutyl acrylate, polyoctadecyl acrylate, copolymer of acrylic and methacrylic acid ester with a lower ammonium group content, copolymer of acrylic and methacrylic acid ester and trimethyl ammonium methacrylate, polyvinyl acetate, polyvinyl acetate phthalate, maleic acid anhydride-vinyl methyl ether, styrene-maleic acid, 2-ethyl-hexyl-acrylate maleic acid anhydride, crotonic acid-vinyl acetate, glutaminic acid/glutamic acid ester, polyarginine, polyethylene, polypropylene, polyethylene oxide, polyethylene terephthalate, polyvinyl isobutyl ether, polyvinyl chloride, polyurethane and vinyl pyrrolidone/dimethylamino ethyl methacrylate.  
   
   
       31 . The composition according to  claim 25  wherein the acrylate ester is polymerized with a monomer selected from the group consisting of N,N-dimethylamino ethyl methacrylate, N,N-diethylamino ethyl acrylate, N,N-diethylamino ethyl methacrylate, N-t-butylamino ethyl acrylate, N-t-butylamino ethyl methacrylate, N,N-dimethylamino propyl acrylamide, N,N-dimethylamino propyl methacrylamide, N,N-diethylamino propyl acrylamide, and N,N-diethylamino propyl methacrylamide.  
   
   
       32 . The composition according to  claim 25  wherein the gel forming polymer is selected from the group consisting of polyethylene oxide, sodium alginate, a homopolymer of acrylic acid cross-linked with allyl sucrose or allylpentaerythritol, and a copolymer of acrylic acid and an alkyl acrylate and cross-linked with allylpentaerythritol, wherein the alkyl group has from 10-30 carbon atoms.  
   
   
       33 . The composition according to  claim 24  wherein the gel forming polymer has a molecular weight of from about 70,000 to about 2,000,000.  
   
   
       34 . The composition according to  claim 24  which additionally comprises a pH modifier.  
   
   
       35 . The composition according to  claim 34  wherein the pH modifier is selected from the group consisting of sodium hydroxide, calcium hydroxide, calcium carbonate, diethyl carbonate, diphenyl carbonate and combinations thereof.  
   
   
       36 . The composition according to  claim 24  wherein the gel forming polymer is present in an amount of from about 2 to about 40 weight percent, based on the total weight of the composition.  
   
   
       37 . The composition according to  claim 24  wherein the central nervous system stimulant is present in an amount of from about 0.1 to about 90 weight percent, based on the total weight of the composition.  
   
   
       38 . The composition according to  claim 24  which is in a form selected from the group consisting of powder, granules, solution, suspension, emulsion and combinations thereof.  
   
   
       39 . A method for the reduction or elimination of the drug abuse potential of central nervous system stimulants by subjects in need of central nervous system stimulation therapy by providing said subjects with a composition comprising 
 (a) a drug selected from the group consisting of methylphenidate, amphetamine, methamphetamine, and combinations thereof; and    (b) a gel forming polymer wherein the gel forming polymer is a polymer that forms a gel when contacted with moisture or placed in an aqueous solution.